These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 12800807)

  • 1. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
    Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
    Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC; Hoem NO; Glauser T; Vinks AA
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.
    Sun H; Ette EI; Ludden TM
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):637-50. PubMed ID: 9300354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.
    Lu J; Gries JM; Verotta D; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):343-62. PubMed ID: 11677931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
    Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
    BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator.
    Rousseau A; Léger F; Le Meur Y; Saint-Marcoux F; Paintaud G; Buchler M; Marquet P
    Ther Drug Monit; 2004 Feb; 26(1):23-30. PubMed ID: 14749545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.
    Yang S; Roger J
    Pharm Stat; 2010; 9(4):313-30. PubMed ID: 20043295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
    Jaber MM; Brundage RC
    J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
    Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
    PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.
    Soy D; Aweeka FT; Church JA; Cunningham CK; Palumbo P; Kosel BW; Sheiner LB;
    Clin Pharmacol Ther; 2003 Dec; 74(6):569-80. PubMed ID: 14663459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
    Periclou AP; Avramis VI
    Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.